Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
8Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Avalo Therapeutics, Inc. (AVTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
1Distinct source URLs
5High confidence
0.751Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from ANRO graph: ts of preparing, filing, and prosecuting patent applications, maintaining and enforcing our intellectual property rights, and defending intellectual property-…
Avalo Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
APOLLO
APOLLO
90%
In the event that J&J and/or Apollo are required to make payment(s) to ES Therapeutics pursuant to the underlying agreements, Avalo will recognize revenue under its existing contracts with those cust…
Reciprocal relationship from JNJ graph: Reciprocal relationship from AVTX graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from AVTX graph: Reciprocal relationship from JNJ grap…
rch 23, 2026, except for the policies as described below. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narro…
APOLLO-AP43-LIMITED
APOLLO-AP43-LIMITED
62%
rch 23, 2026, except for the policies as described below. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narro…
ARMISTICE-CAPITAL-LLC
ARMISTICE-CAPITAL-LLC
62%
rch 23, 2026, except for the policies as described below. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narro…
ES-THERAPEUTICS-LLC
ES-THERAPEUTICS-LLC
62%
rch 23, 2026, except for the policies as described below. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narro…
JANSSEN-PHARMACEUTICS-INC
JANSSEN-PHARMACEUTICS-INC
62%
rch 23, 2026, except for the policies as described below. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narro…
USA-LLC
USA-LLC
62%
e to commercialization of approximately 6.3 years, based on Avalo’s interpretation of Apollo’s September 2025 announcement that the drug met the primary endpoint in its Phase 2a clinical trial in ato…
Avalo Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
AVTX-DEBT-8002
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-12-31.
AVTX-DEBT
Debt stack $15.3M
90%
Market cache reports total debt of $15.3M.
AVTX-DEBT-8001
Warrants outstanding: 4000000
90%
xbrl warrant detail from xbrl 2025-12-31.
Avalo Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Avalo Therapeutics, Inc..
Avalo Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
AVTX-OWNER-FMR-LLC
FMR LLC
90%
13F overlay lists FMR LLC as top holder; 101 tracked holders.
Avalo Therapeutics, Inc. Extended Supply Chain Network
